CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
Nafamostat +1 moredrug
Likely dose
Nafamostat 0.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01001403
NCT01001403Phase 4Completed
CompareCT.gov

Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft

Seoul National University Hospital·interventional·Posted Oct 26, 2009·Updated May 11, 2010

In Brief

A Phase 4 clinical trial evaluating Nafamostat and Normal saline for Liver Transplantation and Postreperfusion Syndrome. Completed, enrolled 62 participants across 1 site.

Detailed Summary

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Transplantation, Postreperfusion Syndrome
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.7 years ago

Interventions

Nafamostatdrug

0.2 mg/kg as bolus 1 minute before reperfusion

Normal salinedrug

10 ml of normal saline